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Abstract
Background: Inferring viral tropism from genotype is a fast and inexpensive alternative to phenotypic testing.
While being highly predictive when performed on clonal samples, sensitivity of predicting CXCR4-using (X4)
variants drops substantially in clinical isolates. This is mainly attributed to minor variants not detected by standard
bulk-sequencing. Massively parallel sequencing (MPS) detects single clones thereby being much more sensitive.
Using this technology we wanted to improve genotypic prediction of coreceptor usage.
Methods: Plasma samples from 55 antiretroviral-treated patients tested for coreceptor usage with the Monogram
Trofile Assay were sequenced with standard population-based approaches. Fourteen of these samples were
selected for further analysis with MPS. Tropism was predicted from each sequence with geno2pheno[coreceptor].
Results: Prediction based on bulk-sequencing yielded 59.1% sensitivity and 90.9% specificity compared to the
trofile assay. With MPS, 7600 reads were generated on average per isolate. Minorities of sequences with high
confidence in CXCR4-usage were found in all samples, irrespective of phenotype. When using the default false-
positive-rate of geno2pheno[coreceptor] (10%), and defining a minority cutoff of 5%, the results were concordant in
all but one isolate.
Conclusions: The combination of MPS and coreceptor usage prediction results in a fast and accurate alternative to
phenotypic assays. The detection of X4-viruses in all isolates suggests that coreceptor usage as well as fitness of
minorities is important for therapy outcome. The high sensitivity of this technology in combination with a
quantitative description of the viral population may allow implementing meaningful cutoffs for predicting response
to CCR5-antagonists in the presence of X4-minorities.
Background
Treatment of HIV infection has progressed significantly
in the last decade. Amongst other factors this improve-
ment is also based on the development of new drugs
which are becoming more and more potent and which
nowadays are given in combination [1]. This so-called
highly active antiretroviral therapy (HAART) aims at
inhibiting the viral replication as strongly as possible by
using antiretroviral drugs from usually two different
drug classes. While mortality and morbidity decreased
substantially, long-term side effects and suboptimal drug
potency are still major obstacles [2]. Moreover, the
emergence of drug-resistant variants from minor
populations may lead to early therapy-failures despite
apparently effective treatment regimes [3].
With the approval of maraviroc (MVC, Celsentry/
Selzentry, Pfizer) [4] in 2007, a further new class of antire-
trovirals was introduced into anti-HIV treatment. In con-
trast to previously approved drugs, drugs from this class
do not bind to viral proteins but to a specific coreceptor
which is expressed by the host cell [5,6]. Two coreceptors
CCR5 and CXCR4 have been shown to be relevant in vivo.
The mode of action of coreceptor antagonists led to the
assumption that administration of such drugs would
impede the adaptation of the virus and consequently lower
the risk of developing resistance. However, the major pro-
blem of coreceptor antagonists is that there are two types
of viruses: 1) so-called R5-viruses which use the CCR5
coreceptor for cell entry and which are usually dominant
in the beginning of infection, and 2) dual-tropic and X4-
viruses, which can also use another coreceptor (CXCR4)
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binds to CCR5, viruses which are capable of using CXCR4
are not harmed by the drug. Therefore, coreceptor usage,
also known as viral tropism, has to be determined before
administration of a regimen containing maraviroc. Cur-
rently such tests are performed with a phenotypic assay,
usually the trofile assay (nowadays the enhanced sensitivity
version) from Monogram Biosciences (San Francisco, CA,
USA) [7]. In this assay a recombinant replication-defective
virus carrying the tropism-determining gp120 V3 region
of a clinical isolate, is analyzed for entry on either CCR5-
or CXCR4 expressing cells. The assay has been used in all
maraviroc and vicriviroc (another coreceptor antagonist
which is not in development anymore, Merck) clinical
trials and has therefore become the de facto gold standard
for measuring coreceptor-tropism. The main disadvan-
tages of phenotypic assays are that they are very time-con-
suming and cost-intensive [8]. Additionally, samples with
viral loads below 1,000 copies/ml or certain non-B sub-
types exhibited an extraordinarily high failure rate in the
original Trofile assay.
Here the genotypic approach poses an alternative. It is
characterized by the experimental determination and
computational interpretation of the viral genome. Geno-
typic prediction of HIV-1 tropism is an inexpensive and
fast alternative to phenotypic assays [8,9]. However, stan-
dard sequencing approaches afford only a low sensitivity
of X4-detection, especially in clinical isolates [10-12].
They generally work well when applied to clonal data
[10,12] which led to the conclusion that “false” predic-
tions are mainly attributed to the lack of detection of
minor populations of CXCR-using variants. To overcome
this disadvantage, a new approach to genotypic tropism
testing, the so-called massively parallel sequencing [13]
was introduced. This technology enables generating an
unprecedented number of sequences on the basis of sin-
gle molecule sequencing, thus increasing the probability
of identifying minority variants in heterogeneous gene
families or virus populations. Therefore, coreceptor usage
prediction from genotype is generally regarded as a pro-
mising application of ultra-deep sequencing, which
detects single clones, thereby being much more sensitive
than classical population-based Sanger sequencing.
In this study we address the question whether mas-
sively parallel sequencing can be successfully combined
with bioinformatic approaches in order to afford
improved qualitative and a quantitative prediction of
coreceptor usage from the V3-loop.
Methods
Patients
Samples from 55 heavily pre-treated patients with lim-
ited therapy options were screened for potential admin-
istration of maraviroc. 3 ml plasma from each patient
was shipped on dry ice for phenotypic tropism testing
(original trofile tropism assay, Monogram Biosciences,
South San Francisco). Plasma viral load was determined
using the M2000 system (Abbott Molecular). Results
were documented as either CCR5-tropic (R5), CXCR4-
tropic (X4) or dual-/mixed-tropic (D/M). X4- and D/M
isolates are pooled together and called X4 from here on.
The investigation was performed within the German
RESINA-study for which the patients signed an
informed consent (BMG 310/4476/02/3).
RNA extraction, cDNA synthesis and V3-PCR
RNA extraction was performed by using the Viral RNA
mini kit (Qiagen, Hilden, Germany) according to the
manufacturer’s instructions. cDNA-synthesis was per-
formed using 10 μl of RNA, specific primers V3-1
(5’TACAATGTACACATGGAATT, position 6958 ®
6977 in HXB2), V3-2 (ATTACAGTAGAAAAATTCCCC,
position 7362 ® 7382 in HXB2) [14] and Superscript II
(Invitrogen) according to the manufacturer’s instructions
in a total volume of 20 μl.
Amplification of the V3 region was carried out using
the FastStart HiFi PCR system, (Roche, Mannheim) and
primers V3-for (TGGCAGTCTAGCAGAAGAAG, posi-
tion 7010 ® 7029 in HXB2) and V3-rev (CTGGGTC
CCCTCCTGAGG, position 7315 ® 7332 in HXB2) [14]
in a Primus 96 plus thermal cycler (MWG-Biotech).
Products to be massively parallel sequenced were gen-
erated with fusion primers V3FusA: GCCTCCCTC
GCGCCATCAG-V3-for and V3FusB: GCCTTGCCA
GCCCGCTCAG-V3-rev.
Standard DNA sequencing and massively parallel
pyrosequencing
Clean-up of the PCR products prior to standard sequen-
cing was performed by incubation with FastAP™ in
conjunction with Exonuclease I (Fermentas, Burlington,
Canada) for 10 min at 37°C followed by heat inactiva-
tion for 5 min at 75°C.
Population-based sequencing of the V3 region was
carried out using the Big Dye
® Terminator v3.1 cycle
sequencing kit (Applied Biosystems, Foster City, CA,
USA) with primers (3pmol) V3-for and V3-rev. Exten-
sion products were purified using the Biomek NXp
automated sequencing reaction cleanup system (Beck-
man Coulter, Fullerton, CA, USA) and were run on an
ABI 3130 capillary sequencer (Applied Biosystems, Fos-
ter City, CA, USA).
Out of the 55 samples, 14 (7 R5, 7 X4) were randomly
selected for further analysis with massively parallel
sequencing. All 14 amplicons were purified with
AMPure magnetic beads (Agencourt, Beckman Coulter)
and quantified using an Agilent 2100 Bioanalyser (Agi-
lent Life Sciences). Since bidirectional sequencing using
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position, unidirectional sequencing with primer A (kit
II; Roche-454 Life Sciences) was chosen to ensure pre-
cise quantification. After beads recovery and enrich-
ment, approximately forty thousand beads were loaded
on each region of a GS FLX PicoTiter plate subdivided
with a 16-lane gasket. Sequencing was performed on a
Genome Sequencer FLX (Roche-454 Life Sciences).
Determination of HIV-coreceptor phenotype
The trofile assay is a single-cycle recombinant virus
assay developed by Monogram Biosciences. A 2.5kb
long part of the patient-derived env gene is amplified by
PCR and inserted into an envelope expression vector.
Together with a replication-defective retroviral vector
carrying a luciferase reporter gene, this vector is used
to co-transfect human embryonic kidney 293 cells
(HEK293). Pseudo-viruses produced by these cells are
then given to engineered U87 target cell lines expressing
either CCR5 or CXCR4.
Upon successful infection of these cells, the reporter
gene is expressed and a light signal emitted. This can be
quantitated in relative light units (RLU) and is addition-
ally controlled by the presence of coreceptor antago-
nists. The original tropism assay is reported to be
reproducible and effective at detecting minority popula-
tions of CXCR4-using virus at levels as low as 5% [7].
Preprocessing of 454-data
Massively parallel sequencing data was processed
directly from the Standard Flowgram Files (.sff) contain-
ing the sequence trace data. The system’sm e t h o d sf o r
post-processing (GS De Novo Assembler, GS Reference
Mapper, GS Amplicon Variant Analyzer) have not been
used due to previous problems with this software
Two main filtering steps were applied to minimize possi-
ble errors and to sort out non-V3 sequences arising from
PCR- or sequencing errors. These worked as follows: First,
sequences were translated into all three reading frames.
Each frame was then screened for typical start and end-
motifs of the V3-loop (e.g. CTR, CIR, AHC, AYC). Only
sequences where both ends of the loop were recognized
in the same reading frame were further processed. The
potential V3-loop was cut out and its length analyzed.
While the usual V3-loop has a length of about 35 amino
acids, loops containing a number of insertions and dele-
tions have been observed previously, as well [11]. To allow
for such indels but limit the number of deviations from
the standard loop which could occur due to sequencing
problems, we introduced the criteria that V3-loops had to
have a length of at least 30 and at most 45 residues. If sev-
eral V3-start- or V3-end motifs were found in a specific
read, only the one with the length closest to 35 was
selected for coreceptor usage prediction.
Tropism prediction from genotype
Genotypes resulting from both sequencing methods
were input to a development version of geno2pheno
[coreceptor] for coreceptor usage prediction (version
from June 2009) [11]. This version of the freely available
web system produces exactly the same predictions as
the public version but differs in two respects: First, it
can process a number of sequences in batch allowing to
handle the vast amount of data generated with the Gen-
ome Sequencer FLX system and second it returns the
internal scores of the prediction method which are
currently not displayed on the website (the displayed
FPR-scores are a transformation of these scores ).
Prediction results were used in two fashions: On the
one hand, cutoffs corresponding to the false-positive rates
available on the website (1%, 2.5%, 5%, 10%, 15%, 20%)
were used in order to classify the samples into R5- and
X4-viruses. On the other hand, the raw values were used
for detailed quantitative analysis as described below.
Performance assessment
For performance comparison, the Monogram Trofile
assay was used as reference. Performance was measured
in terms of accuracy, true positive rate and false positive
rate. The true positive rate is the relative number of X4
viruses correctly predicted as X4 while the false positive
rate is the relative number of R5 viruses falsely classified
as X4. Accuracy represents the total agreement between
genotype and phenotype. For all evaluations, the statisti-
cal programming language R [15] was used.
Analysis of the error rate
The 454 GS-20 system is reported to have an overall error
rate of 0.4% [16] to 0.49% [17] whereas the error rate of
the FLX system is supposed be about 0.12% [16]. For the
GS-20 system, only about 11% [16] to 16% [17] of all
errors turned out to be substitution errors whereas the
remaining errors are insertion and deletion errors. Thus,
the per-base substitution error rate is approximately
0.042% [16] to 0.078% [17]. A nucleotide error might not
necessarily change the amino acid of the respective codon
and thus the prediction score. When checking the number
of possible synonymous and non-synonymous mutations,
we found 460 of 576 possible codon mutations to be non-
synonymous. Therefore, the probability of a problematic
substitution error in these reports is reduced to 0.03354%
and 0.0623%, respectively. Given a V3-loop of 105 nucleo-
tides, the probability of having no error is therefore
(1-0.0335%)
105 = 96.54% and (1-0.0623%)
105 = 93.66% and
consequently the probability of an erroneous V3 amino
acid sequence only 3.4% to 6.3%. Considering the fact that
not every amino acid change will change the coreceptor
prediction we assume that such errors do not affect our
results substantially.
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be unproblematic because they induce frame shifts.
These are detected by our filtering approach testing for
valid V3-ends at both sides of the loops. Last but not
least, it might happen that within a V3-loop an insertion
and a deletion error occur together so that the V3-ends
are in the same frame. However, reads with more than
one sequence error occurred only in 7% of the reads in
[17]. Taken into account that both errors have to be
located within the V3-loop which is much smaller than
the whole read and one of them has to be an insertion
and one a deletion error the probability of such a case is
negligibly small, too.
Based on these considerations we can assume that our
results should not be affected too much by problems
with the sequencing technology.
Results
Bulk-sequencing results
Prediction results based on population-sequenced iso-
lates were compared with tropism calls generated by the
trofile assay (see Table 1). Using the default false-posi-
tive rate of geno2pheno (10%), 43 of the 55 isolates
were predicted concordantly with the Monogram Trofile
Tropism Assay. For 9 out of 22 samples phenotyped to
be X4 by the trofile assay, geno2pheno[coreceptor] pre-
dicted an R5-virus. On the other hand, for 3 of the 33
v i r u s e sd e t e r m i n e db yt h et r o f i l ea s s a ya sR 5 ,g e n o 2 -
pheno returned an X4-prediction. Hence, the sensitivity
of predicting CXCR4-using isolates was 59.1% while
specificity was at 90.9%. These prediction results are in
line with results reported in recent publications
[10,11,18-20]. The overall accuracy with respect to the
trofile assay was 78.2%.
454-results
General statistics
Table 2 shows characteristics of the individual samples
analyzed with the GS FLX system. On average, around
7600 (range: 885-12992) reads were generated per iso-
late. The variation in the number of generated reads per
sample remained unclear. It was not significantly corre-
lated with the viral load (r
2 = 0.042). The mean viral
load was at 35810 copies per milliliter.
After translation and adjusting for the V3-loop we
found 280 different amino acid variants of the V3-loop
on average (range: 57-584). The squared correlation coef-
ficient between the number of different V3-variants and
the number of reads was r
2 =0 . 5 8 4( p=0 . 0 0 1 ) .W h e n
comparing R5- and X4 isolates, we did not find any sig-
nificant difference between the two groups neither for
the number of reads generated (p = 0.29, 8821 vs. 6341),
nor for the viral load (p = 0.26, 19515 vs. 52106) or the
number of found V3-loops (p = 0.29, 6808 vs. 4687) and
their variants (p = 0.97, 281.7 vs. 279.1).
Quantitative analysis of coreceptor usage
All reads in which a consistent V3-loop sequence was
found were input to the geno2pheno[coreceptor] prediction
system. This resulted in around 7,600 coreceptor predic-
tions per isolate. Since this vast amount of data cannot
be interpreted easily we decided to display the results in
a plot in addition to tabulating numbers. Figure 1 shows
the results for two isolates. Every individual point in
these plots represents the prediction score of one read.
The score of the prediction which can be regarded as an
affinity value is plotted along the y-axis. High scores
represent predictions for which geno2pheno[coreceptor]
was very confident of the virus being X4 (low false-posi-
tive rates) whereas low scores represent viruses probably
being R5. The shape of the curve qualitatively reflects
the coreceptor usage of the whole population within the
relevant isolate. E.g. the population depicted in Figure
1a consists of almost exclusively R5-viruses whereas Fig-
ure 1b depicts a virus population about half of which
can use the CXCR4-receptor.





Comparison of trofile-results and geno2pheno predictions from bulk-
sequenced isolates tested for maraviroc administration.
Table 2 Properties of analyzed patient isolates
isolate trofile viral load,
copies/ml
#reads #reads with v3
loop
#variants
1 X4 65815 885 667 67
2 X4 3236 4614 3205 233
3 X4 28850 3875 2825 210
4 X4 199005 12063 10091 325
5 X4 10082 12013 9608 584
6 X4 9400 3094 1581 147
7 X4 48354 7847 4833 388
8 R5 48000 10622 8621 354
9 R5 9300 1601 344 57
10 R5 16400 6105 4905 216
11 R5 11928 11142 8677 301
12 R5 1270 11551 8748 283
13 R5 18709 12992 10555 320
14 R5 31000 7740 5808 441
Characteristics of the isolates sequenced with the 454-machine. The number
of variants is the number of different amino acid sequences found for the v3
loop.
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frequency of predicted X4-viruses for the specific false-
positive rates on the geno2pheno website (see Figure 2).
These are useful when one is interested in the question
how many viruses are predicted to be X4 at a specific
cutoff. While being more easily to interpret than the
previous type of graph, the global picture of the viral
population is lost. E.g. from Figure 1b one can easily
infer that the viral population is split into two major
strains while this is not possible from Figure 2b.
Comparison between genotypic prediction and
phenotypic results
In order to obtain a qualitative prediction from the
ultra-deep data, two cutoffs have to be defined. The first
is a cutoff for the prediction score has to be selected -
reflecting the affinity of the virus to the CXCR4-core-
ceptor. For this purpose and in order to be comparable
to the bulk-sequenced isolates, we chose the cutoff
resulting in the standard 10% false-positive rate of gen-
o2pheno[coreceptor]. Second, we have to set a minority
threshold because in every sample individual clones very
predictive for CXCR4-usage had been found. Three
reasons might be responsible for this: (i) not every min-
ority is clinically relevant, (ii) the phenotypic assay also
has a sensitivity limit which has to be taken into
account and which is most probably higher than the
limit for massively parallel sequencing, and (iii) in some
cases the 454-machine also produces erroneous
sequences that are not recognized during preprocessing
and prediction and which should not have an impact on
the overall prediction outcome. Hence, we decided to
select a minority cutoff of 5%, i.e. only samples in which
more than 5% of the sequences were predicted to be
CXCR4-using were assigned to be X4. This value is
identical with the proposed sensitivity limit of the stan-
dard trofile assay used in this analysis.
By applying these settings to the dataset, we could
achieve concordance with the phenotypic assay in all
but one case (isolate 7, see Table 3).
Discussion
In this work, we analyzed the usefulness of next-genera-
tion sequencing technologies in the realm of coreceptor
usage prediction. Our results show that the approach
Figure 1 Overview of coreceptor usage predictions from one sample (a: isolate 13, Trofile R5; b: isolate 5, Trofile X4).E v e r yd o t
represents the prediction for one read. The colors indicate at which FPR-cutoff, the read would have been predicted as X4.
Figure 2 Proportion of predicted X4-viruses at different FPR in ultra deep sequenced V3 amplicons (a: isolate 13 Trofile R5; b: isolate
5, Trofile X4).
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quantitatively assessing the tropism of the viral quasispe-
cies. With respect to the classification, our results are con-
cordant with the phenotype in all cases but one. It should
be noted that the cutoffs selected in this work were not
optimized. Instead we selected cutoffs which are plausible
(default cutoff of the geno2pheno method and the pro-
posed sensitivity limit of the phenotypic assay). On the
other hand, due to the limited amount of data, it was not
possible to infer the cutoffs automatically in a statistically
sound way. Future work on larger datasets should focus
on optimizing the cutoffs. The data set on which we base
this study is too small for this purpose. However, when
comparing the results to the predictions obtained with
conventional bulk-sequencing approaches it could clearly
be shown that combining genotypic prediction with ultra-
deep sequencing provides a fast and accurate alternative to
phenotypic assays.
In addition to simple classification of the isolates into
R5- and X4-samples, we could also provide a quantita-
tive output with this approach. This may be of minor
interest when comparing against a phenotype as done in
this work but can be more important in the context of
administration of coreceptor antagonists. A patient with
a very small minority of X4-viruses might respond dif-
ferently to a regimen containing coreceptor antagonist
than a patient with a majority of X4-viruses despite the
fact that both might have an X4-phenotype. However,
this has to be addressed in the future when larger data-
sets with therapy outcome become widely available.
The main advantage of the massively parallel sequen-
cing technology implemented in the GS FLX-system is
that it can reliably detect minor variants and generate
clonal sequences. In the context of coreceptor usage,
especially the first property seems to be of special inter-
est because minor variants have been shown to be much
m o r ei m p o r t a n ti nt r o p i s md e t e r m i n a t i o nt h a ni nH I V
resistance testing.
The main disadvantage of the 454-technology is that
currently it is rather expensive with costs for a run ran-
ging around 10,000€. However, several samples can be
sequenced in parallel in a single run so that it is possible
to lower the per/sample price dramatically (e.g. by
sequencing 48 patients in parallel the price will decrease
to about 200€). The drawback is that usually not that
many patients have to be screened at the same time.
Nevertheless, sequencing prices will further decrease so
that we believe that this technology will be standard in
the future.
I nt h ec o u r s eo ft h i sw o r k ,s o m ep u b l i c a t i o n sh a v e
become available dealing with coreceptor usage and mas-
sively parallel sequencing. Tsibris et al. [21] have used
the 454-technology to monitor the evolution and escape
o fH I V - 1d u r i n gC C R 5a n t a g o n i s tt h e r a p yi nf o u r
patients but not to predict the tropism of these viruses.
In a related work, Archer et al. [22] used the 454 Gen-
ome Sequencer 20 to find minorities of CXCR4-using
variants emerging in a patient treated with maraviroc
monotherapy. In contrast to our work, however, these
two works did not focus on the prediction of viral trop-
ism but on the observation of shifts within the viral qua-
sispecies under selective drug pressure. More recently,
approaches similar to the one discussed here have been
presented by Abbate et al. [23] and Vandekerckhove et
al. [24]. Swenson et al. used such a method to rescreen
the patients enrolled in the MOTIVATE studies and
compared the results with the ones generated by the ori-
ginal trofile assay [25,26]. In a related study it was also
found that genotypic interpretation of data from popula-
tion-based sequencing works much better than antici-
pated despite substantial discordant rates to the original
trofile assay [27].
The original trofile assay used in this work has been
replaced by an enhanced version (ESTA) able to detect
minor variants circulating in quantities as low as 0.3%.
This might imply that more differences with the new
assay would have been seen than with the old assay.
However, we believe that this is not the case for two
reasons: First of all, we have set the minority cutoff to
5% to mirror the one of the original trofile assay which
was reported to be 100% sensitive at detecting 10%










1 X4 2.5% 85.3%
2 X4 5% 87.0%
3 X4 10% 14.2%
4 X4 15% 5.4%
5 X4 15% 48.0%
6X 4 —
c 68.5%
7X 4 — 1.0%
8 R5 10% 1.4%
9R 5 — 3.4%
10 R5 — 0.3%
11 R5 — 0.5%
12 R5 — 1.6%
13 R5 — 1.8%
14 R5 — 2.4%
Tropism results from different approaches used: phenotype (trofile),
coreceptor usage prediction from bulk-genotype, and coreceptor usage
prediction from massively parallel sequencing.
FPR: false-positive-rate of geno2pheno.
athe displayed value is the highest cutoff at which an isolate would have
been predicted as X4.
bdefault geno2pheno[coreceptor]-cutoff of 10% FPR used.
c ’—’ if predicted FPR, was above the highest cutoff tested (20%).
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variants in a mixed virus population. We could easily
lower this cutoff to any other value. Second, we have
presented data at the 7
th European HIV Drug Resistance
Workshop [28] on how to adjust the FPR cutoff of gen-
o2pheno[coreceptor] in order to obtain prediction
results comparable in terms of sensitivity and specificity
of X4-detection on samples generated with the original
and the enhanced sensitivity trofile assays. The same
adjustment could be applied in this case as well.
Additional data would definitively strengthen the results.
However, we cannot afford the high costs to screen further
samples with the Trofile assay and with the 454-technol-
ogy. Moreover, we would now get the results from the
enhanced sensitivity Trofile and not the original Trofile
used in this study. Thus, we would also have to rescreen
the 14 samples used in this analysis again.
There is room for improvements. First, as already dis-
cussed above one has to decide if the goal is to recreate
the results of Trofile-assay or rather to reliably predict
coreceptor antagonist admissibility. In our opinion the
latter is more important. Therefore the 5%-minority cut-
off chosen in this project is probably not the best solu-
tion and should be adjusted when more treatment data
become available. In fact, the 5% cutoff appears high
with respect to the possibilities of ultradeep sequencing.
We chose it since we compare the 454 technology
against an assay for which a minority threshold of about
5% is suitable. If we used a cutoff of 1%, the samples 8
and 12-14 would also be predicted as X4 by massively
parallel sequencing but not by the Trofile assay. We
could then claim that the 454 assay is more sensitive
than the Trofile assay. Others might say, however, that
these samples are erroneously classified as X4 on the
basis of the 454 measurements. Thus, we feel that a fair
comparison is only possible if we use the same sensitiv-
ity limits for both assays compared.
Furthermore, one might think about changing the
dogma to exclude all patients from a therapy with core-
ceptor antagonists who harbor a dual-tropic or X4-virus.
We found at least one sequence predicted as X4 in
every isolate which means that if we do not use a min-
ority cutoff none of our patients would be administered
a coreceptor antagonist. This does not make therapeutic
sense. Instead of trying to further increase the sensitivity
of detecting minority populations we suggest to search
for clinically relevant cutoffs. These cutoffs might not
only be based on the number of minor X4-viruses but
also depend on the fitness of these variants. McGovern
et al. [27] determined and proposed a clinical cutoff at
FPR of 5.75%. However, this cutoff was based on tripli-
cate sequencing in which the lowest predicted FPR was
used. Consequently, these FPRs were lower in general
than those for single sequencing making a direct com-
parison difficult. We feel that with respect to the pheno-
type, the standard 10% g2p cutoff is more appropriate.
Another point one to be addressed in the future is
that we used a standard coreceptor prediction tool
which was originally developed for bulk-sequenced iso-
lates and not for ultra-deep data. This might imply pro-
blems because e.g. the prediction system also uses
features like the number of ambiguous positions which
are usually not or only rarely existent in massively paral-
lel sequencing data. Thus, a tool trained specifically on
the latter kind of sequence data should show enhanced
prediction outcomes.
Finally, coreceptor antagonists are administered
together with other antiretroviral compounds. We do
not know if minorities of X4-viruses accumulate the
same resistance mutations to other drugs as the predo-
minant R5-viruses. There mig h tb et h ep o s s i b i l i t yt h a t
these variants have quite different polymerase-genes and
therefore are resistant against a coreceptor antagonist
but not against the other drugs in the backbone. Hence,
a future goal is to sequence the whole virus with the
ultra-deep sequencing technology in order to address
this problem.
Conclusions
Massively parallel sequencing can be successfully com-
bined with prediction of HIV-1 coreceptor usage from V3
genotype. Such an approach results in a fast and accurate
alternative to phenotypic assays which not only gives a
qualitative tropism result but also allows for generating a
quantitative picture of the whole viral quasispecies.
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